// App-Quantinova.ai

: Persistent blood eosinophilia and COPD exacerbation risk after ICS withdrawal from triple therapy in the SUNSET study

Researchers

Presenter

  • John R. Hurst

Principal Investigators

  • Konstantinos Kostikas

  • Kenneth R. Chapman

  • Stefan-Marian Frent

  • Michael Larbig

  • Robert Fogel

  • Tadhg Guerin

  • Donald Banerji

  • Francesco Patalano

  • Pankaj Goyal

  • Pascal Pfister

  • Jadwiga A. Wedzicha

Medical Centers

  • UCL Respiratory, University College London, London, United Kingdom

  • Novartis AG, Basel, Switzerland

  • Asthma and Airway Centre, University Health Network, University of Toronto, Toronto, ON, Canada,

  • Department of Morphopathology, University of Medicine and Pharmacy V. Babes, Timisoara, Romania

  • Novartis Pharmaceuticals Corporation East Hanover NJ United States

  • Novartis Ireland Ltd., Dublin, Ireland

  • Airway Disease Infection Section, National Heart and Lung Institute (NHLI), Imperial College London, London, United Kingdom.

Locations

  • United Kingdom

  • Switzerland

  • Canada

  • Romania

  • United States

  • Ireland

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • salmeterol + fluticasone

  • Seebri Breezhaler

  • Fluticasone

  • Fluticasone furoate

  • indacaterol

  • Salmeterol Xinafoate

  • Tiotropium bromide

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved